| dbo:abstract
|
- Azasetron is an antiemetic which acts as a 5-HT3 receptor antagonist, pKi = 9.27 It is used in the management of nausea and vomiting induced by cancer chemotherapy (such as cisplatin chemotherapy). Azasetron hydrochloride is given in a usual dose of 10 mg once daily by mouth or intravenously. It is approved for marketing in Japan, and marketed exclusively by Torii Pharmaceutical Co., Ltd. under the trade names "Serotone I.V. Injection 10 mg" and "Serotone Tablets 10 mg". Pharmacokinetics data from S. Tsukagoshi. R-azasetron besylate (SENS-401) has been studied to prevent hearing loss related to sudden sensorineural hearing loss (SSNHL), acoustic trauma, and cisplatin-induced ototoxicity. (en)
- アザセトロン（Azasetron、開発コードY-25130）とは、5-HT3受容体アンタゴニストに分類される制吐薬である。1987年に日本で創製され、1994年1月に注射剤が、1999年6月に錠剤が製造承認された。 (ja)
|
| dbo:bioavailability
| |
| dbo:casNumber
| |
| dbo:chEMBL
| |
| dbo:fdaUniiCode
| |
| dbo:kegg
| |
| dbo:pubchem
| |
| dbo:thumbnail
| |
| dbo:wikiPageExternalLink
| |
| dbo:wikiPageID
| |
| dbo:wikiPageLength
|
- 5246 (xsd:nonNegativeInteger)
|
| dbo:wikiPageRevisionID
| |
| dbo:wikiPageWikiLink
| |
| dbp:atcPrefix
| |
| dbp:bioavailability
| |
| dbp:c
| |
| dbp:casNumber
| |
| dbp:chembl
| |
| dbp:chemspiderid
| |
| dbp:cl
| |
| dbp:excretion
| |
| dbp:h
| |
| dbp:iupacName
|
- N--6-chloro-4-methyl-3-oxo-1,4-benzoxazine-8-carboxamide (en)
|
| dbp:iupharLigand
| |
| dbp:kegg
| |
| dbp:n
| |
| dbp:o
| |
| dbp:pubchem
| |
| dbp:routesOfAdministration
| |
| dbp:smiles
|
- CN1CCOc2c1cccc2CNC3CN4CCC3CC4 (en)
|
| dbp:stdinchi
| |
| dbp:stdinchikey
|
- WUKZPHOXUVCQOR-UHFFFAOYSA-N (en)
|
| dbp:unii
| |
| dbp:verifiedrevid
| |
| dbp:wikiPageUsesTemplate
| |
| dcterms:subject
| |
| rdf:type
| |
| rdfs:comment
|
- アザセトロン（Azasetron、開発コードY-25130）とは、5-HT3受容体アンタゴニストに分類される制吐薬である。1987年に日本で創製され、1994年1月に注射剤が、1999年6月に錠剤が製造承認された。 (ja)
- Azasetron is an antiemetic which acts as a 5-HT3 receptor antagonist, pKi = 9.27 It is used in the management of nausea and vomiting induced by cancer chemotherapy (such as cisplatin chemotherapy). Azasetron hydrochloride is given in a usual dose of 10 mg once daily by mouth or intravenously. It is approved for marketing in Japan, and marketed exclusively by Torii Pharmaceutical Co., Ltd. under the trade names "Serotone I.V. Injection 10 mg" and "Serotone Tablets 10 mg". Pharmacokinetics data from S. Tsukagoshi. (en)
|
| rdfs:label
|
- Azasetron (en)
- アザセトロン (ja)
|
| owl:sameAs
| |
| prov:wasDerivedFrom
| |
| foaf:depiction
| |
| foaf:isPrimaryTopicOf
| |
| is dbo:wikiPageRedirects
of | |
| is dbo:wikiPageWikiLink
of | |
| is foaf:primaryTopic
of | |
